No description available

Interviews point to lack of post-discharge care instructions, navigation

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) survivors encounter rare, life-threatening drug reactions and years of physical, emotional

These alerts summarize FDA updates to Prescribing Information for medications used in epilepsy, but may also include relevant news about devices or dietary treatments from other sources.

Scinai Immunotherapeutics introduces PC111, a groundbreaking therapy shown to modify diseases like pemphigus and SJS/TEN, with promising safety and efficacy data.

Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.

Stevens-Johnson syndrome and its more severe variant, toxic epidermal necrolysis, are rare and dangerous immunologic diseases. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) result in rapid-onset keratinocyte apoptosis and inflammation causing blistering and sloughing of the skin and the mucosal epithelium that lines the mouth, eyes and eyelids (Kohanim et al.). SJS/TEN is usually induced by an adverse reaction to medication, most commonly antibiotics, antiepileptics and allopurinol. However, mycoplasma infections may also trigger a similar but clinically distinct condition

Stevens-Johnson syndrome and its more severe variant, toxic epidermal necrolysis, are rare and dangerous immunologic diseases. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) result in rapid-onset keratinocyte apoptosis and inflammation causing blistering and sloughing of the skin and the mucosal epithelium that lines the mouth, eyes and eyelids (Kohanim et al.). SJS/TEN is usually induced by an adverse reaction to medication, most commonly antibiotics, antiepileptics and allopurinol. However, mycoplasma infections may also trigger a similar but clinically distinct condition